ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

STX Shield Therapeutics Plc

2.85
-0.10 (-3.39%)
22 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -3.39% 2.85 2.80 2.90 2.95 2.85 2.90 2,684,036 08:23:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 13.09M -33.29M -0.0429 -0.66 22.88M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.95p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 7.65p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £22.88 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.66.

Shield Therapeutics Share Discussion Threads

Showing 21351 to 21372 of 21500 messages
Chat Pages: 860  859  858  857  856  855  854  853  852  851  850  849  Older
DateSubjectAuthorDiscuss
15/11/2024
17:16
When i sthe €1 million from Pediatruc studay to be received ??
krp10
15/11/2024
12:48
Funny - Bobath is trying to troll me on GSK even though I'm apparently filtered and don't exist. Clearly lying is in the fabric of his personality
dplewis1
15/11/2024
11:23
RICHARD BOBARTH news article www.mirror.co.uk/news/uk-news/conman-jailed-swindling-41000-working-8810621.amp
antonagis
15/11/2024
11:22
How many mugs are invested here? Do you all still feel confident in anything whatsoever PURCHASEATTHETOP (RICHARD BOBARTH) or his disciples such us ZEUS have to say? You were all warned and I was mocked by a couple of his disciples a few weeks ago when at 4.5p. Who is laughing now? He’ll continue to post all day every day until this is completely worthless and then move on to ramp another worthless stock. Check his posting history on every single stock he’s ever ramped since he joined ADVFN.
antonagis
15/11/2024
10:43
“Although there had been some recovery in the share price to ca.5.Op, following the 3Q'24 trading update, the market has become more concerned about the continuing commercial risk and the debate about gross cash. This was exacerbated by the updated view that Shield needed to agree a share subscription for a minimum of $10m from its major shareholder, AOP Health, to get it to cashflow-breakeven. The market needs to see further benefits of the enlarged sales team in each sequential quarter in order to have the confidence to rerate the shares.”

Seems accurate enough. Whether the extra risk means the share price should halve when the Rx seems just below $200 now when it was $119 a year ago and prescriptions have doubled in a year!

The market seems to be assuming more failures by the new lesdership just like the Madison crew. Maybe not this time.

purchaseatthetop
15/11/2024
10:07
Slide 10 had good info. $325k incoming from KYE with the Canadian launch scheduled for next quarter
zeus19
15/11/2024
10:04
Cheers Zeus. Seems pretty definite!

“Shield is being proactive, extending its working capital financing from $10m to $15m and issuing $10m new shares to AOP, to manage the company through to cashflow-breakeven in 2H25.”

“Sequential 3Q'24 Rx growth of 20%, to 43,500, was modestly below expectations (28%). Combined with the weak July selling price, sales, at $7.2m, were below our $7.9m forecast. However, the higher $192 selling price in the latter months of 3Q'24 is expected to be maintained throughout 4Q'24.”

“Management is being very proactive in the management of gross cash in order to take the company through to cashflow-breakeven in 2H'25.”

purchaseatthetop
15/11/2024
09:38
https://hardmanandco.com/wp-content/uploads/2024/11/November-2024-Hardman-Co-Investor-Forum-Programme.pdfPresentation pack
zeus19
15/11/2024
09:26
Any feedback from Hardman & co investor forum event held on 14th Nov
krp10
13/11/2024
20:30
RICHARD BOBARTH with the same old line about an RNS. It’s priceless repetition on every board he’s been on since he joined ADVFN.
antonagis
13/11/2024
19:42
Would be timely to have a funding RNS 7am tomorrow.
purchaseatthetop
13/11/2024
17:51
Shield Therapeutics plcShield Therapeutics plc
5,423 followers5,423 followers
2h • Edited • 2 hours ago
On 14 November, Anders Lundstrom, Interim CEO, and Santosh Shanbhag, CFO, will be joining the panel for the Hardman & Co Investor Forum.

We look forward to discussing the impact of changes in the global markets on healthcare investments and exploring new growth avenues in the sector. Join us as we share our insights and connect with fellow investors and industry experts.
Register now to participate, ask questions, and gain valuable insights here:

purchaseatthetop
12/11/2024
21:23
Recruiting in Austin, Texas



22 applicants in a day.

purchaseatthetop
12/11/2024
20:54
Certainly is.My Mum is early 70's. On blood pressure tablets. Got a blood test recently and her iron levels were 8. Should be between 10&30. The further we move away from the land and consume highly processed foods the more this will become a problem.
r9505571
12/11/2024
17:35
Quite a big potential market to grow into!



CNN

You may have an iron deficiency and not even know it.

A large proportion of adults in the United States – nearly 1 in 3 – may have one of two forms of iron deficiency, even if they don’t have a health condition for which they would be screened for it, such as anemia, heart failure or chronic kidney disease, a new study suggests.

The study, published Tuesday in the medical journal JAMA Network Open, warns that iron deficiency may be a “widespread” and “underrecognized” public health problem in the United States.

purchaseatthetop
12/11/2024
14:45
Interesting comparisons between STX and CREO. So thanks to Parob for coming to the board to try to upset me.

CREO have spent £157m if retained losses getting to losing £10m every six months.
Overhead of £40m a year. Sales about £30m. No revenue growth. 47% gross margin.

STX have spent about the same of retained losses getting to losing the same amount every six months. Overhead about the same. 250% revenue growth with similar revenue now. same gross margin. Likely £65m plus revenue 2025.

STX market cap £21k
CREO market cap £75m

Certainly seems one is under or overvalued. Very similar in many ways.

purchaseatthetop
12/11/2024
12:46
No you are lying AGAIN. I never said the growth rate is bad.I have been telling investors to be careful of you and your posts.
parob
12/11/2024
12:44
PATT has starting knocking CREO so you can expect the price to start rising imo. Contra indicator.
parob
12/11/2024
12:35
Actually if you want a real laugh, Parob is pumping CREO.

Revenue static at £10m every six months
Gross margin static at 47%
Cash burn of £10m every six months.
Going concern active with them relying on selling a part of their business “expected Q1 25” but subject to numbers of future uncertainties.

And he thinks STX with its 250% growth rate is bad.

purchaseatthetop
12/11/2024
11:06
I thought you had me filtered?Another lie.
parob
12/11/2024
10:58
I don’t know why Parob is here posting when I had never posted anything on any of his boards. However, that has now changed. Parob can get used to me doing exactly the same to him. Makes it even don’t you think.
purchaseatthetop
12/11/2024
10:30
Large sells going through under the bid price now.Is PATT still ramping?
parob
Chat Pages: 860  859  858  857  856  855  854  853  852  851  850  849  Older

Your Recent History

Delayed Upgrade Clock